7512-78-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-phenylfuran-2(5H)-one is used as a pharmaceutical candidate for its potential biological activities. Its unique molecular structure allows it to be a promising agent for the development of new drugs.
Used in Biotechnology:
In the biotechnology field, 3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-phenylfuran-2(5H)-one is utilized for its potential applications in the study and manipulation of biological processes. Its complex structure may offer novel ways to interact with biological systems.
Used in Material Science:
3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-phenylfuran-2(5H)-one is also used in material science to explore its potential in creating new materials with unique properties. Its complex molecular structure may contribute to the development of advanced materials with specific applications.
Further research is necessary to fully understand the properties and potential uses of 3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-phenylfuran-2(5H)-one in these fields.

Upstream product

• 98-86-2 acetophenone 
• 169802-93-1 2-(benzo[d][1,3]dioxol-5-yl)-4-oxo-4-phenylbutanenitrile 
• 644-34-8 (E)-3-(benzo[d][1,3]dioxol-5-yl)-1-phenylprop-2-en-1-one 
• 120-57-0 piperonal 
• 169802-94-2 2-benzo[1,3]dioxol-5-yl-4-oxo-4-phenyl-butyric acid methyl ester 
• 100-52-7 benzaldehyde 

Relevant academic research and scientific papers

NONPEPTIDE ENDOTHELIN ANTAGONISTS I

Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.

Structure-activity relationships in a series of orally active γ- hydroxy butenolide endothelin antagonists

The design of potent and selective non-peptide antagonists of endothelin-1 (ET-1) and its related isopeptides are important tools defining the role of ET in human diseases. In this report we will describe the detailed structure-activity relationship (SAR) studies that led to the discovery of a potent series of butenolide ET(A) selective antagonists. Starting from a micromolar screening hit, PD012527, use of Topliss decision tree analysis led to the discovery of the nanomolar ET(A) selective antagonist PD155080. Further structural modifications around the butenolide ring led directly to the subnanomolar ET(A) selective antagonist PD156707, IC50's = 0.3 (ET(A)) and 780 nM (ET(B)). This series of compounds exhibited functional activity exemplified by PD156707. This derivative inhibited the ET(A) receptor mediated release of arachidonic acid from rabbit renal artery vascular smooth muscle cells with an IC50 = 1.1 nM and also inhibited the ET-1 induced contraction of rabbit femoral artery rings (ET(A) mediated) with a pA2 = 7.6. PD156707 also displayed in vivo functional activity inhibiting the hemodynamic responses due to exogenous administration of ET-1 in rats in a dose dependent fashion. Evidence for the pH dependence of the open and closed tautomerization forms of PD156707 was demonstrated by an NMR study. X- ray crystallographic analysis of the closed butenolide form of PD156707 shows the benzylic group located on the same side of the butenolide ring as the γ- hydroxyl and the remaining two phenyl groups on the butenolide ring essentially orthogonal to the butenolide ring. Pharmacokinetic parameters for PD156707 in dogs are also presented.